Literature DB >> 30247602

Point-Counterpoint: The Hope-Simpson Hypothesis and Its Implications Regarding an Effect of Routine Varicella Vaccination on Herpes Zoster Incidence.

Rafael Harpaz1, Albert J van Hoek2.   

Abstract

Some 50 years ago, Edgar Hope-Simpson published his hypothesis regarding the interactions between varicella and herpes zoster. As part of this hypothesis, Hope-Simpson postulated that reactivation of varicella zoster virus (VZV) was under immunological control, and that this immunological control could be boosted "endogenously" due to reactivation of latent VZV, and "exogenously" due to exposure to varicella. This hypothesis has important policy implications and remains a source of debate today; namely, does reducing VZV circulation through effective pediatric varicella vaccination programs lead to unintended increases in herpes zoster (HZ) incidence? This article provides 2 very different perspectives on this issue. The first perspective (Rafael Harpaz: Evidence Against an Effect) highlights the empiric experience of the United States, with its population of >300 million, a highly effective national varicella vaccination program lasting >20 years, and with several credible sources of data regarding HZ incidence. The US data have shown an increase in HZ incidence that preceded the availability of varicella vaccination by decades; indeed, HZ rates appear to have plateaued among older adults since varicella vaccination was introduced. Furthermore, HZ rates are not different in states having higher vs lower preschool varicella vaccination rates. The second perspective (Albert J. van Hoek: Evidence for an Effect) cites data that persons with close exposure to children appear to be at lower risk of HZ before universal VZV vaccination, but not so thereafter. Due to historic demographic changes, exogenous boosting could play a role in explaining the observed increase in HZ before varicella vaccination. Thus, it might be difficult to separate declines in exogenous boosting due to demographic changes from those caused by the varicella vaccination program. Additional data will be needed to conclusively rule out an impact of varicella vaccination on HZ.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30247602     DOI: 10.1093/infdis/jiy418

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Safety and Varicella Outcomes in In Utero-Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program.

Authors:  Jennifer M Duchon; Myron J Levin; Anne A Gershon
Journal:  J Pediatric Infect Dis Soc       Date:  2020-09-17       Impact factor: 3.164

2.  Herpes zoster in older adults in Ontario, 2002-2016: Investigating incidence and exploring equity.

Authors:  Sarah A Buchan; Nick Daneman; Jun Wang; Sarah E Wilson; Gary Garber; Anne E Wormsbecker; Tony Antoniou; Shelley L Deeks
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

Review 3.  Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines.

Authors:  Eric I Benchimol; Frances Tse; Matthew W Carroll; Jennifer C deBruyn; Shelly A McNeil; Anne Pham-Huy; Cynthia H Seow; Lisa L Barrett; Talat Bessissow; Nicholas Carman; Gil Y Melmed; Otto G Vanderkooi; John K Marshall; Jennifer L Jones
Journal:  J Can Assoc Gastroenterol       Date:  2021-07-29

Review 4.  Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review.

Authors:  Catherina X Pan; Michelle S Lee; Vinod E Nambudiri
Journal:  Ther Adv Vaccines Immunother       Date:  2022-03-21

5.  Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom.

Authors:  Esse Ifebi Herve Akpo; Olivier Cristeau; Manjit Hunjan; Giacomo Casabona
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.